Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
暂无分享,去创建一个
J. Tabernero | J. Jassem | J. Canon | Y. Humblet | G. Bodoky | P. Ruff | M. Błasińska-Morawiec | D. Cunningham | S. Patterson | J. Douillard | R. Williams | F. Rivera | S. Siena | J. Wiezorek | R. Burkes | K. Oliner | M. Barugel | I. Kocáková | M. Šmakal | M. Rother | A. Rong | R. Sidhu
[1] C. Tournigand,et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] E. Van Cutsem,et al. Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.
[3] E. Van Cutsem,et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] John D Potter,et al. BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[5] C. Bokemeyer,et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.
[6] C. Bokemeyer,et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] Sabine Tejpar,et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. , 2011, The Lancet. Oncology.
[8] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Larissa V Furtado,et al. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer , 2011, Genes, chromosomes & cancer.
[10] A. Fernández-Medarde,et al. Ras in cancer and developmental diseases. , 2011, Genes & cancer.
[11] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[12] V. Lemmens,et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Bardelli,et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.
[16] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[17] Barry S Taylor,et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. , 2010, Cancer research.
[18] R. Pearson,et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .
[19] G. Fontanini,et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.
[20] P. Jänne,et al. Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[21] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[22] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Robert A. Weinberg,et al. Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.
[24] M. Meyerson,et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients , 2008, British Journal of Cancer.
[25] J. Stachura,et al. KRAS mutation profile in colorectal carcinoma and novel mutation--internal tandem duplication in KRAS. , 2008, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[26] J. Manola,et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.
[27] Y. Okamoto,et al. SurveyorTM nuclease-based detection of p53 gene mutations in haematological malignancy , 2007, Annals of clinical biochemistry.
[28] Sarah Edkins,et al. Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.
[29] M. Stratton,et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.
[30] H. Kindler,et al. Metastatic colorectal cancer , 2001, Current treatment options in oncology.
[31] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.